Sagimet Biosciences Inc. updated its investor presentation on April 27, 2026, detailing clinical progress for denifanstat and TVB-3567 in acne and MASH, strong IP position, and $175M stock offering to fund operations through 2028.
Key takeaways
Updated investor presentation furnished under Item 7.01 with clinical pipeline and financial updates.
Denifanstat met all primary/secondary endpoints in Ascletis' Phase 3 acne trial; NDA accepted by China NMPA in Dec 2025.
US Phase 3 acne trial for denifanstat planned for 2H 2026, contingent on regulatory consultation.
TVB-3567 Phase 1 FIH trial initiated June 2025; Phase 2 POC anticipated 2H 2026.
$175M Series A Common Stock offering announced April 2026 to fund operations through 2028 and denifanstat Phase 3 readout.
Cash position $113.1M as of 12/31/2025 and $104.5M as of 3/31/2026 (unaudited).